Clifford Swan Investment Counsel LLC Sells 1,057 Shares of Edwards Lifesciences Co. (NYSE:EW)

Clifford Swan Investment Counsel LLC reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 253,262 shares of the medical research company’s stock after selling 1,057 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Edwards Lifesciences were worth $19,311,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Martin Capital Advisors LLP lifted its position in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after purchasing an additional 128 shares during the period. Legacy Wealth Asset Management LLC raised its stake in Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 134 shares during the last quarter. DMC Group LLC boosted its stake in Edwards Lifesciences by 4.5% in the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after purchasing an additional 154 shares in the last quarter. Granite Harbor Advisors Inc. grew its position in Edwards Lifesciences by 4.2% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after purchasing an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC increased its stake in Edwards Lifesciences by 2.7% during the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock valued at $449,000 after purchasing an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total value of $2,487,999.50. Following the transaction, the director now directly owns 4,486 shares in the company, valued at $380,278.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total value of $2,487,999.50. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $380,278.22. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.83, for a total transaction of $944,130.00. Following the completion of the transaction, the vice president now owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Over the last three months, insiders have sold 237,749 shares of company stock worth $20,920,934. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Mizuho increased their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Citigroup lifted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $0.19 during trading hours on Friday, reaching $85.25. The stock had a trading volume of 2,327,197 shares, compared to its average volume of 3,001,614. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $51.37 billion, a PE ratio of 36.75, a PEG ratio of 3.59 and a beta of 1.10. The stock’s 50 day moving average is $90.08 and its 200 day moving average is $79.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. Equities analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.